The Draft PMPRB Guidelines were released yesterday to explain how the amended Patented Medicines Regulations, that go into effect July 1, 2020 will be implemented.

Forteo (teriparatide, Lilly) is a biologic manufactured using recombinant DNA technology.

The Regulations regarding mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs) by hospitals, proposed last summer, have now been adopted and will come into effect by December 16, 2019.

Universal, single-payer, public pharmacare in Canada.

It has been some time coming but the speculation is over now. BC is the first province to switch patients from certain innovator biologics to their biosimilars.

Biosimilars no longer need to be reviewed by CADTH.

For industry, the path of the biologic prescription, once written, may see a number of influence points that affect market share, marketing plans, patient support programs (PSPs) and prescribers.

Ontario’s Ministry of Health and Long-Term Care (MOHLTC) has proposed legislation regarding pharmacy reimbursement and payment policies.

The sale of Canadian prescription drugs to US citizens continues to garner attention from the FDA, US Senators, the media and American patients.

The Feds are amending the Food and Drug Regulations to improve access to generics.